Actively Recruiting

Age: 18Years +
All Genders
NCT05991206

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

Led by Hunan Province Tumor Hospital · Updated on 2023-12-27

200

Participants Needed

1

Research Sites

135 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

CONDITIONS

Official Title

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must be 18 years or older
  • Provide fully informed consent before any study procedures
  • Have untreated, histologically confirmed resectable stage II, IIIA, or IIIB (N2) NSCLC (AJCC stage VIII), confirmed by PET-CT or biopsy
  • Resectable stage II NSCLC defined by assessment of radical resection by a qualified thoracic surgeon
  • Resectable and potentially resectable stages defined by Expert Consensus on Stage III NSCLC (2019 version)
  • Resectable includes IIIA (N0-1), some single-station mediastinal lymph node metastases with N2, and some T4 (satellite nodules in adjacent lobes) N1
  • Potentially resectable includes some IIIA and IIIB, including single-station N2 mediastinal lymph nodes < 3 cm, stage IIIA NSCLC, and potentially resectable T3 or T4 central tumors
  • Solid or solid pulmonary nodules strongly recommended for pathological puncture verification
  • Have at least one measurable lesion per RECIST 1.1
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hunan Cancer Hospital

Changsha, Hunan, China, 410013

Actively Recruiting

Loading map...

Research Team

Y

Yongchang Zhang, MD

CONTACT

N

Nong Yang

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here